文献速递前列腺癌男科与性医学

保留血管的放疗用于局限性前列腺癌以保护勃起功能:一项单臂2期试验

Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial.
PubMed 文献 · Eur Urol · 2017-02-21

这项单臂2期试验在单个学术中心纳入135例局限性前列腺癌男性,采用计划MRI和MRI血管造影勾画并避开勃起血管实施保留血管放疗。2年勃起功能率为78%(95%CI 71-85%),显著优于常规放疗模型率42%(95%CI 38-45%;p<0.001)和神经保留前列腺切除术模型率24%(95%CI 22-27%;p<0.001);5年和10年生化无复发生存率分别为99.3%和89.9%。作者认为保留血管放疗似乎能更有效保护勃起功能并维持肿瘤控制,但需独立验证。

要点

  • 保留血管放疗2年勃起功能率78%,显著高于常规放疗模型率42%和神经保留前列腺切除术模型率24%。
  • 5年时88%患者有性活动(使用或不使用性辅助手段),87%基线勃起功能保留者维持适合性交的勃起。
  • 5年和10年生化无复发生存率分别为99.3%和89.9%,5年生化失败限于美国国家综合癌症网络高危组。

核心结论

  • 保留血管放疗与历史系列和模型预测的神经保留前列腺切除术或常规放疗后结局相比,似乎能更有效保护勃起功能,同时维持肿瘤控制。
  • 作者认为该方法需要独立验证。

研究设计与样本

  • 单臂2期试验(NCT02958787),在单个学术中心纳入局限性前列腺癌男性。
  • 2001年至2009年共135例男性接受保留血管放疗;计划中期分析达到主要终点后试验停止。
  • 中位随访8.7年,各时间点所有问卷应答率≥94%。

主要发现

  • 5年时88%患者有性活动(使用或不使用性辅助手段)。
  • 2年勃起功能率:保留血管放疗78%(95%CI 71-85%)vs 常规放疗模型率42%(95%CI 38-45%;p<0.001),保留血管放疗较高。
  • 2年勃起功能率:保留血管放疗78%(95%CI 71-85%)vs 神经保留前列腺切除术模型率24%(95%CI 22-27%;p<0.001),保留血管放疗较高。
  • 治疗2年后,87%基线勃起功能保留的男性维持适合性交的勃起。
  • 5年和10年生化无复发生存率分别为99.3%和89.9%;5年时生化失败限于美国国家综合癌症网络高危组。

关键数值与推荐

  • 2年勃起功能率保留血管放疗78%(95%CI 71-85%)vs 常规放疗模型率42%(95%CI 38-45%;p<0.001)。
  • 2年勃起功能率保留血管放疗78%(95%CI 71-85%)vs 神经保留前列腺切除术模型率24%(95%CI 22-27%;p<0.001)。
  • 5年和10年生化无复发生存率分别为99.3%和89.9%。
  • 5年时88%患者有性活动(使用或不使用性辅助手段)。
  • 治疗2年后87%基线勃起功能保留的男性维持适合性交的勃起。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 单臂设计是局限性。
  • 作者认为该方法需要独立验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erectile dysfunction remains the most common side effect from radical treatment of localized prostate cancer. We hypothesized that the use of vessel-sparing radiotherapy, analogous to the functional anatomy approach of nerve-sparing radical prostatectomy (RP), would improve erectile function preservation while maintaining tumor control for men with localized prostate cancer. OBJECTIVE: To determine erectile function rates after vessel-sparing radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: Men with localized prostate cancer were enrolled in a phase 2 single-arm trial (NCT02958787) at a single academic center. INTERVENTION: Patients received vessel-sparing radiotherapy utilizing a planning MRI and MRI-angiogram to delineate and avoid the erectile vasculature. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Both physician- and patient-reported inventories were used to capture erectile function at baseline and at 2 and 5 yr after treatment. Validated model-based comparisons were performed to compare vessel-sparing results to nerve-sparing RP and conventional radiotherapy. RESULTS AND LIMITATIONS: From 2001 to 2009, 135 men underwent vessel-sparing radiotherapy. After a planned interim analysis, the trial was stopped after meeting the primary endpoint. The median follow-up was 8.7 yr, with a ≥94% response rate to all inventories at each time point. At 5 yr, 88% of patients were sexually active with or without the use of sexual aids. The 2-yr erectile function rates were significantly improved with vessel-sparing radiotherapy (78%, 95% confidence interval [CI] 71-85%) compared to modeled rates for convention radiotherapy (42%, 95% CI 38-45%; p<0.001) or nerve-sparing prostatectomy (24%, 95% CI 22-27%; p<0.001). At 2 yr after treatment, 87% of baseline-potent men retained erections suitable for intercourse. The 5- and 10-yr rates of biochemical relapse-free survival were 99.3% and 89.9%, and at 5 yr the biochemical failures were limited to the National Comprehensive Cancer Network high-risk group. The single-arm design is a limitation. CONCLUSIONS: Vessel-sparing radiotherapy appears to more effectively preserve erectile function when compared to historical series and model-predicted outcomes following nerve-sparing RP or conventional radiotherapy, with maintenance of tumor control. This approach warrants independent validation. PATIENT SUMMARY: In this interim analysis we looked at using a novel approach to spare critical erectile structures to preserve erectile function after prostate cancer radiotherapy. We found that almost 90% of patients at 5 yr after treatment remained sexually active, significantly higher than previous studies with surgery or radiotherapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Spratt DE, Lee JY, Dess RT, et al. Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. Eur Urol. 2017. PMID: 28233591. doi:10.1016/j.eururo.2017.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。